MedTrace Logo

Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia

NCT00712686 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 690

Last updated 2013-11-08

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy and tolerability of aripiprazole to olanzapine over 26 weeks for the treatment of schizophrenia

Conditions

Interventions

DRUG

Aripiprazole

Tablets, Oral, 15-30 mg, once daily, 140 weeks

DRUG

Olanzapine

Capsule, Oral, 10-20 mg, once daily, 140 weeks

Sponsors & Collaborators

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-06-30
Primary Completion
2003-12-31
Completion
2003-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00712686 on ClinicalTrials.gov